These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Recent advances in the treatment of type II diabetes mellitus. Baliga BS; Fonseca VA Am Fam Physician; 1997 Feb; 55(3):817-24. PubMed ID: 9048504 [TBL] [Abstract][Full Text] [Related]
7. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Scheen AJ Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641 [TBL] [Abstract][Full Text] [Related]
9. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Strowig SM; Raskin P Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007 [TBL] [Abstract][Full Text] [Related]
11. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study]. García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485 [TBL] [Abstract][Full Text] [Related]
12. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus. Graham JP; Stam D Pharm Pract Manag Q; 1997 Oct; 17(3):1-9. PubMed ID: 10173306 [TBL] [Abstract][Full Text] [Related]
13. The role of troglitazone in treating the insulin resistance syndrome. Granberry MC; Schneider EF; Fonseca VA Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309 [TBL] [Abstract][Full Text] [Related]
14. Type 2 diabetes: glycemic targets and oral therapies for older patients. Lardinois CK Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974 [TBL] [Abstract][Full Text] [Related]
15. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856 [TBL] [Abstract][Full Text] [Related]
16. Pharmacologic management of diabetes mellitus. Mozersky RP J Am Osteopath Assoc; 1999 Dec; 99(12 Suppl):S15-9. PubMed ID: 10659525 [TBL] [Abstract][Full Text] [Related]
17. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976 [TBL] [Abstract][Full Text] [Related]
18. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Kumar S; Prange A; Schulze J; Lettis S; Barnett AH Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807 [TBL] [Abstract][Full Text] [Related]
19. The use of insulin alone and in combination with oral agents in type 2 diabetes. Buse JB Prim Care; 1999 Dec; 26(4):931-50. PubMed ID: 10523468 [TBL] [Abstract][Full Text] [Related]
20. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]